Previous Article | Next Article ![]()
Infection and Immunity, June 2004, p. 3515-3523, Vol. 72, No. 6
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.6.3515-3523.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Institut National de Sante et de Recherche Medicale (INSERM U 430), Immunopathologie Humaine, 75006 Paris, France,1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland 20892-1820,2 Department of Cell and Molecular Biology, Lund University, SE-22184 Lund, Sweden3
Received 3 December 2003/ Returned for modification 24 January 2004/ Accepted 23 February 2004
Some pathogens have evolved to produce proteins, called B-cell superantigens, that can interact with human immunoglobulin variable regions, independently of the combining site, and activate B lymphocytes that express the target immunoglobulins. However, the in vivo consequences of these interactions on human B-cell numbers and function are largely unknown. Using transgenic mice expressing fully human immunoglobulins, we studied the consequences of in vivo exposure of protein L of Peptostreptococcus magnus with human immunoglobulins. In the mature pool of B cells, protein L exposure resulted in a specific reduction of splenic marginal-zone B cells and peritoneal B-1 cells. Splenic B cells exhibited a skewed light-chain repertoire consistent with the capacity of protein L to bind specific kappa gene products. Remarkably, these two B-cell subsets are implicated in innate B-cell immunity, allowing rapid clearance of pathogens. Thus, the present study reveals a novel mechanism that may be used by some infectious agents to subvert a first line of the host's immune defense.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»